These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. Miller PD, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR. Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140 [Abstract] [Full Text] [Related]
23. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Orsolini G, Gatti D. Clin Exp Rheumatol; 2015 Oct; 33(1):77-83. PubMed ID: 25438096 [Abstract] [Full Text] [Related]
25. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S. J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967 [Abstract] [Full Text] [Related]
26. Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients. Das S, Bopitya S, Chowdhury AR, Das A, Taha H. Recent Pat Antiinfect Drug Discov; 2016 Mar; 11(1):59-67. PubMed ID: 26844688 [Abstract] [Full Text] [Related]
27. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab. Mosali P, Bernard L, Wajed J, Mohamed Z, Ewang M, Moore A, Fogelman I, Hampson G. Calcif Tissue Int; 2014 May; 94(5):553-9. PubMed ID: 24509506 [Abstract] [Full Text] [Related]
28. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women. Kharroubi A, Saba E, Smoom R, Bader K, Darwish H. Arch Osteoporos; 2017 Dec; 12(1):13. PubMed ID: 28124221 [Abstract] [Full Text] [Related]
32. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D. J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689 [Abstract] [Full Text] [Related]
33. Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. Kaji H, Hisa I, Inoue Y, Naito J, Sugimoto T, Kasuga M. J Bone Miner Metab; 2009 Dec; 27(1):76-82. PubMed ID: 19018454 [Abstract] [Full Text] [Related]
38. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women. Adami S. Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041 [Abstract] [Full Text] [Related]
39. The effect of season and vitamin D supplementation on bone mineral density in healthy women: a double-masked crossover study. Patel R, Collins D, Bullock S, Swaminathan R, Blake GM, Fogelman I. Osteoporos Int; 2001 Nov; 12(4):319-25. PubMed ID: 11420782 [Abstract] [Full Text] [Related]